Strathspey Crown Wins US Patent for Titration of Phenotypic (DNA) Expression

NEWPORT BEACH, Calif., Feb. 5, 2018 /PRNewswire/ -- Strathspey Crown LLC announced today that the US Patent and Trademark Office issued a novel patent (US Patent 9,877,892; named Inventors: Robert Edward Grant, Matthew T. Case, and Todd Mirzai MD) for the titration of both genotype and phenotypic (DNA) expression and differentiation using varying oscillating frequencies of sonic electromagnetism on targeted in-vivo cellular structures.  

The genotype is the set of genes in our DNA, which is responsible for a particular trait. The phenotype is the physical expression, or characteristics, of that genetic trait interacting with environmental factors. Phenotypic expression defines the physical genetic expression of DNA, including genetic traits determining height, hair-color, eye-color, facial characteristics, susceptibility to particular disease conditions and cell mutations including cancer, heart disease, neurodegenerative disorders and diabetes, among many others.  Mammalian lifespan and telomerase expression is also an expression of phenotype.

The primary claim of US Patent 9,877,892 is a system and method of directing vibrational oscillating sonic waves toward a target tissue in the body of a person to influence both genotype and phenotypic differentiation of the target tissue at a cellular level, including a sonic generator wherein predetermined frequency from the program to monitor and entrain, via an epidermal patch, the desired phenotypic response from the targeted in-vivo cellular structure.

Strathspey Crown LLC Chairman and lead co-inventor, Robert E. Grant commented, "We are very pleased to expand our intellectual property portfolio in this exciting field with this important and highly attractive commercial sector addressing manipulation of human genetic expression.  This groundbreaking sector has already been targeted by many leading genetic and pharmaceutical researchers and corporations.  Titration of phenotypic expression has been referred to as the 'Holy Grail' of the genetic research community and thus may represent a major advance in disease management, lifestyle enhancement and significantly extending life.  We strongly believe that precisely targeted sonic wave electromagnetism will eventually provide a fundamental new treatment modality controlling disease predilection and expression."

Grant further commented, "This patent is only one within a rapidly expanding IP portfolio at Strathspey Crown that we are confident will have far-reaching ramifications for genetic expression; potentially leading to numerous life-enhancing and life-extending medical applications.  Strathspey Crown presently has several other patent applications in pending status with the US Patent and Trademark office, each addressing significant future market segments across medicine, genetic expression, as well as, miniature implantable smart-ocular technologies integrating cameras, an LED display, wireless connectivity and solar recharging ability, including augmented reality-ready ocular implantable technologies."

About Strathspey Crown LLC: Strathspey Crown is a growth equity firm specializing in lifestyle healthcare. The firm's subsidiaries and investors include board certified physician specialists across key medical specialties, including plastic surgery, ophthalmology, dermatology, dentistry and orthopedics. Strathspey Crown is focused on working with physician investors to bring to market innovative technologies and services in the self-pay sector of the lifestyle healthcare market. For more information, please visit www.strathspeycrown.com.

STRATHSPEY CROWN LLC Press Contact: 
Diana Fraser, Director 
Tel: +1 949.260.1700 
Email: [email protected]

SOURCE Strathspey Crown LLC